-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Maintains Outperform on Xeris Biopharma Holdings, Raises Price Target to $16

Benzinga·09/10/2026 15:15:11
Listen to the news
Leerink Partners analyst Roanna Ruiz maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Outperform and raises the price target from $12 to $16.